You are here: Industry Insights > Sunovion

News List

Sunovion and Otsuka Initiate Phase 3 Clinical Development of Treatment for Bipolar Depression AmericanPharmaceuticalReview
February 10, 2022
Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced that the first patient has been randomized in SEP380-301...
Cipla gets USFDA nod for inhalation product expresspharma
June 25, 2021
The approved product is a generic version of Sunovion Pharmaceuticals Inc's Brovana.
Lupin launches generic version of Brovana in US expresspharma
June 04, 2021
Lupin announced the launch of the authorised generic version of Brovana (arformoterol tartrate) Inhalation Solution 15 mcgꝉ/2 mL, unit-dose vials, of Sunovion Pharmaceuticals.
Sunovion gets FDA nod for Kynmobi to treat Parkinson’s disease off episodes pharmaceutical-business-review
May 27, 2020
Sunovion Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its Kynmobi (apomorphine hydrochloride) sublingual film (APL-130277) to treat Parkinson’s disease (PD) off episodes.
Sunovion Announces FDA Filing Acceptance of Resubmitted NDA for Apomorphine Sublingual Film americanpharmaceuticalreview
December 24, 2019
Sunovion Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for apomorphine sublingual film (APL-130277) ...
Sunovion, PsychoGenics nondopamine schizophrenia drug meets phase 2 endpoint fiercebiotech
December 26, 2018
Sunovion Pharmaceuticals and PsychoGenics unveiled positive phase 2 results for a new schizophrenia treatment that does not bind to the brain’s dopamine receptors.....
FDA rejects Sunovion’s ADHD drug pharmatimes
September 14, 2018
Sunovion’s application to market dasotraline for the treatment of attention-deficit hyperactivity disorder (ADHD) has been rejected by US regulators.
Sunovion's Parkinson's Drug Succeeds in Late-Stage Trial biospace
January 31, 2018
Sunovion Pharmaceuticals today announced its key Phase III clinical trial
Pharma companies fall foul of ABPI’s Code of Practice pharmatimes
December 14, 2017
Sunovion Pharmaceuticals Europe, Bayer, Astellas UK, Astellas Europe and Menarini Pharma UK SRL have been named in adverts for breaching of the ABPI’s Code of Practice.
Sunovion Announces FDA Acceptance for NDA Review of Dasotraline americanpharmaceuticacreview
November 13, 2017
The NDA submission is supported by multiple placebo-controlled safety and efficacy studies, as well as two long-term studies that assessed the safety of dasotraline in people with ADHD for up to one year.

Previous page 1 2 Next page